NIAID Supports Ebright's Latest Project

Richard Ebright, Professor II in the Department of Chemistry and Chemical Biology at the School of Arts and Sciences and laboratory director at the Waksman Institute of Microbiology, Rutgers–New Brunswick, is the principal investigator of a grant totaling $5.15 million. The project titled Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins is being supported by the Partnerships for Development of Therapeutics and Diagnostics for Biodefense program at the National Institute for Allergy and Infectious Diseases. The proposed work is expected to provide new drug candidates effective against a broad spectrum of drug-resistant bacterial pathogens, including both public-health-relevant bacterial pathogens and biodefense-relevant bacterial pathogens. This will be the second of two concurrent Partnerships for Development of Therapeutics and Diagnostics for Biodefense grants to Professor Ebright. Learn more about Professor Ebright here.